- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Dapagliflozin Metformin in T2D: Five Evidence Insights Relevant for Clinicians

Diabetes affects an estimated 589 million adults worldwide, nearly one in nine, and is projected to reach 853 million by 2050. 1 Yet, T2D rarely presents in isolation: the same diagnosis may coexist with obesity, fatty liver disease, cardiorenal risk, or age-related bone loss, each reshaping treatment priorities. 2-4 For clinicians, the real question is no longer simply how much HbA1c can be lowered, but how one therapeutic choice performs across these different clinical phenotypes.
Dapagliflozin–metformin FDC has been in global use for over a decade, with EU approval in 2014 and DCGI approval in India in 2017, and is approved across 61 countries, including the United States, European Union and Japan. 5
The following five evidence insights explore how dapagliflozin–metformin performs across clinically distinct T2D phenotypes, moving the discussion from glucose lowering to phenotype-driven care.
1. Dapagliflozin–Metformin FDC: Initial Choice in Indian T2D
The multi-centre, retrospective ADMIRE study evaluated 485 Indian adults with T2D and HbA1c >7% who were initiated on dapagliflozin–metformin FDC and followed for 6 months. Mean age was 59.7±9.8 years and diabetes duration 6.9±4.7 years; dapagliflozin 10 mg/metformin 500 mg was the most commonly used dosage strength. At 6 months, HbA1c decreased by 2.19%, FPG by 21.4 mg/dL, and PPG by 37.1 mg/dL (all p<0.0001). Hypoglycaemia and genitourinary infections were reported in 16.7% and 8.9%, respectively. These findings highlight the real-world glycaemic effectiveness and tolerability of dapagliflozin–metformin FDC in Indian T2D practice. 6
2. Overweight or Obese T2D with Dapagliflozin-Metformin FDC: Targeting Glycemic and Metabolic Burden
In a 12-week randomized pilot study of 60 adults with T2D and obesity, dapagliflozin 5 mg added to metformin 500 mg twice daily significantly improved HbA1c, FBS, PPBS, waist, neck and hip circumference, triglycerides, LDL, insulin and resistin versus metformin alone; HDL and growth hormone increased, while BMI was unchanged. 7
Reinforcing its clinical relevance, a 2025 published clinical survey of 914 Indian clinicians found 68.27% preferred dapagliflozin–metformin FDC as initial combination therapy in overweight/obese T2D, while 72.31% cited weight reduction as an important factor for its use. 8 Together, these findings support dapagliflozin–metformin as a clinically relevant approach in T2D with obesity, addressing glycaemic control alongside the broader metabolic burden.
3. T2D with MASLD: Extending Benefits to Liver Health with Dapagliflozin-Metformin FDC
In a 16-month study including 45 patients with T2D and NAFLD, dapagliflozin 10 mg/day plus metformin up to 2,000 mg/day reduced FPG from 195.5±8.6 to 169.2±8.3 mg/dL (−26.3 mg/dL) and BMI from 31.04±0.63 to 29.55±0.50 kg/m² (−1.49 kg/m²) (p<0.05).
The NAFLD Fibrosis Score (NFS) improved from −0.941±0.11 to −1.61±0.12 (p<0.001), indicating a shift toward lower fibrosis risk. After treatment, nearly two-thirds of patients were classified in the mild fibrosis category (64.9% vs 27.6% at baseline), while the proportion in the indeterminate category fell from 72.6% to 35.1%, showing an overall improvement in liver fibrosis markers.
These findings suggest concurrent improvement in glycaemic control, adiposity and non-invasive markers of hepatic fibrosis with dapagliflozin–metformin therapy.9
4. T2D with Cardiorenal Risk: Protection Beyond Glycemic Control with Dapagliflozin-Based Treatment
In DECLARE–TIMI 58, 17,160 patients with T2D were randomized to dapagliflozin 10 mg/day or placebo and followed for a median 4.2 years. Mean age was 63.8 years, diabetes duration 11.8 years and baseline HbA1c 8.3%; 40.6% had established ASCVD and 59.4% had multiple cardiovascular risk factors. Importantly, 14,068 patients (82%) were receiving metformin at baseline. Dapagliflozin reduced the relative risk of cardiovascular death or heart-failure hospitalization by 17% (HR 0.83; 95% CI 0.73–0.95) and the renal-specific outcome by 47% (HR 0.53; 95% CI 0.43–0.66). These findings suggest the benefits of addition of dapagliflozin to metformin-based therapy in T2D patients where cardiorenal risk extends beyond glycaemic control alone. 10
5. Older T2D with Osteoporosis: Factoring Bone Health Alongside Glycemia with Dapagliflozin-Metformin FDC
In a 12-month prospective randomized double-blind study, Zheng et al. evaluated 144 elderly patients (60–75 years) with T2D and osteoporosis assigned to metformin alone (n=72) or dapagliflozin 5 mg/day plus metformin 500 mg twice daily (n=72). Combination therapy achieved greater reductions in FPG from 168.5±26.8 to 115.2±16.6 mg/dL (−53.3 mg/dL), 2hPG from 231.1±24.3 to 153.2±14.4 mg/dL (−77.9 mg/dL), and HbA1c from 8.87±1.10% to 6.22±0.78% (−2.65%) versus metformin alone. It also improved BMD at L1–4 (0.720±0.082 to 0.809±0.094 g/cm²), femoral neck and total hip, with lower fracture incidence (4.2% vs 13.8%). These findings suggest dapagliflozin–metformin may provide metabolic benefits alongside favourable bone-related outcomes in elderly T2D patients with osteoporosis. 11
Figure 1: Considering Dapagliflozin–Metformin in T2D Across Different Patient Phenotypes
Integrating Evidence into Clinical Decisions
Beyond glycaemic efficacy, contemporary T2D management increasingly focuses on the interconnected pathways contributing to disease progression and long-term outcomes. Emerging evidence has explored the potential role of dapagliflozin and metformin in modulating inflammatory pathways, oxidative stress and metabolic dysregulation. 12, 13
Following GLP-1 RA discontinuation, dapagliflozin–metformin FDC may represent a pragmatic oral strategy in overweight/obese individuals with T2D, supporting continued glycaemic and weight management while retaining the established cardiorenal benefits of dapagliflozin, when clinically appropriate. 14
Additionally, fixed-dose combinations may help address treatment complexity and pill burden, which remain important determinants of long-term adherence in chronic disease management. Pharmaco-economic evaluations further emphasize the relevance of balancing therapeutic effectiveness with healthcare resource utilization and affordability. 15 Collectively, these insights support individualized, risk-based treatment strategies aligned with patient phenotype and clinical priorities.
Final Message
Across distinct T2D phenotypes, from patients requiring initial combination therapy and those with obesity or MASLD to individuals with cardiorenal risk or coexisting osteoporosis – evidence suggests that dapagliflozin metformin FDC can provide glycemic control alongside clinically relevant metabolic and comorbidity-related benefits, supporting its use across diverse patient profiles.
Abbreviations
T2D: Type 2 Diabetes; HbA1c: Glycated Haemoglobin; FDC: Fixed-Dose Combination; ADMIRE: Assessing Dapagliflozin And Metformin As An Initial Regimen In Diabetes Mellitus For Enhanced Glucose Control; FPG: Fasting Plasma Glucose; PPG: Postprandial Glucose; MASLD: Metabolic Dysfunction-Associated Steatotic Liver Disease; NAFLD: Non-Alcoholic Fatty Liver Disease; LDL: Low-Density Lipoprotein; HDL: High-Density Lipoprotein; BMD: Bone Mineral Density; ASCVD: Atherosclerotic Cardiovascular Disease; CKD: Chronic Kidney Disease; HF: Heart Failure; DECLARE–TIMI 58: Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58; HR: Hazard Ratio; CI: Confidence Interval.
- 1.Genitsaridi I, Salpea P, Salim A, Sajjadi SF, Tomic D, James S, Thirunavukkarasu S, Issaka A, Chen L, Basit A, Luk AOY, Ma RCW, Mbanya JC, Ramachandran A, Wild SH, Duncan BB, Boyko EJ, Magliano DJ. 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050.Lancet Diabetes14149-156
- 2. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).J Hepatol.81492-542
- 3. American Diabetes Association Professional Practice Committee for Diabetes*. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026.Diabetes Care.49216-245
- 4.Brandt IAG, Starup-Linde J, Andersen SS, Viggers R. Diagnosing Osteoporosis in Diabetes-A Systematic Review on BMD and Fractures.Curr Osteoporos Rep.22223-244
- 5. Press Trust of India. AstraZeneca Pharma India gets DCGI nod to market diabetes drug. Business Standard. 2017 Oct 17.
- 6.Phadke DU, Gopal DJ, Biswas DK, Birla DA, Prasad A, Joshi P. FRI649 ADMIRE: Assessing Dapagliflozin And Metformin As An Initial Regimen In Diabetes Mellitus For Enhanced Glucose Control.J Endocr Soc.7
- 7.Naganathan, S., Mohapatra, S., Raja, S. et al. Effect of Dapagliflozin–Metformin Combination Therapy on Metabolic-Regulating Hormones in Obese Patients with Type 2 Diabetes: A Randomized Controlled TrialSN Comprehensive Clinical Medicine
- 8.Agrawal M, Ahluwalia A, Boddula R, Baidya A, Saikia H, Mathew A, Naryanan P, R A, Reddy MN, Kesarkar RN, Pednekar A. Indian Clinicians' Perspectives on Utilizing Dapagliflozin-Based Combination Therapy for the Management of Obesity in Patients With Type 2 Diabetes Mellitus.Cureus.17
- 9.OLGA LAVRYNENKO, NONNA KRAVCHUN, OLHA ZEMLIANITSYNA, INNA DUNAEVA, RALPH A. DEFRONZO, EUGENIO CERSOSIMO, IURIY KARACHENTSEV; 1226-P: Antifibrotic Effect of Combination Dapagliflozin and Metformin Therapy in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.Diabetes
- 10.Cahn A, Wiviott SD, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, Rozenberg A, Wilding JPH, Leiter LA, Bhatt DL, McGuire DK, Litwak L, Kooy A, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Raz I. Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.Diabetes Obes Metab.23
- 11.Zheng H, Wang Q, Si M. Dapagliflozin combined with metformin improves blood glucose, bone metabolism and bone mineral density in elderly patients with type 2 diabetes mellitus complicated with osteoporosis.Kaohsiung J Med Sci.41
- 12.Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential.Nat Rev Endocrinol.19
- 13.Senoz O, Sezen M. Effects of Dapagliflozin on Novel Inflammatory Markers in Heart Failure Patients.Cardiol Res Pract.
- 14.Davies MJ, Aroda VR, Bajaj M, ElSayed NA, Giorgino F, Green J, Kalyani RR, Maruthur NM, Mathieu C, Rosas SE, Rossing P, Slater T, Tankova T, Topsever P, Tsapas A, Buse JB. Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia.
- 15.Cruz-Gallegos LA, Villarreal-Ríos E, Blanco-Castillo L, Galicia-Rodríguez L. Cost-effectiveness of dual treatment with metformin-sitagliptin versus metformindapagliflozin in patients with type 2 diabetes.Gac Med Mex.
Dr M. Shunmugavelu is a Physician and Diabetologist and Chairman & Managing Director of Trichy Diabetes Speciality Centre, Trichy. He holds MD in General Medicine and is a Fellow of the Indian College of Physicians (FICP), Royal College of Physicians, Glasgow (FRCP), and Research Society for the Study of Diabetes in India (FRSSDI). He has extensive experience in diabetes care, clinical research and medical education.

